Mineralys Therapeutics (MLYS)

What Moves the Stock

1. 01Phase 3 trial design announcements and FDA alignment on registration pathway for lorundrostat
2. 02Clinical data readouts showing blood pressure reduction magnitude, durability, and safety versus standard of care
3. 03FDA regulatory milestones including IND clearances, breakthrough therapy designation potential, and NDA submission timing
4. 04Partnership announcements or licensing deals that validate lorundrostat's commercial potential and provide non-dilutive funding
5. 05Equity financing announcements and terms (dilution concerns versus runway extension)
6. 06Competitive developments in resistant hypertension space including Bayer's finerenone, Idorsia's aprocitentan
7. 07No current revenue - pre-commercial clinical-stage company
8. 08Future potential: Lorundrostat commercial sales if approved (estimated 2028-2029 earliest)

MLYS Chart

My Notes

• growth/speculative - Attracts biotech-specialized investors, hedge funds with event-driven strategies around clinical catalysts…
• Rising interest rates negatively impact MLYS through two channels: (1) Valuation compression - pre-revenue biotechs are valued on discounted…
• Watch on earnings: Phase 3 trial enrollment milestones and patient randomization rates versus guidance, Quarterly cash burn rate and remaining runway to key clinical readouts, Blood pressure reduction data (systolic/diastolic mm Hg) versus baseline and competitive benchmarks.